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MRI Findings and Prediction of Time to Progression of Patients 
with Hepatocellular Carcinoma Treated with Drug-eluting Bead 
Transcatheter Arterial Chemoembolization
The purpose of this study was to investigate the utility of MRI findings after drug-eluting 
beads (DEB) - transcatheter arterial chemoembolization (TACE) for hepatocellular 
carcinoma in predicting time to progression (TTP). This study included 48 patients with 60 
lesions who underwent liver MRI within 3 months after DEB-TACE. MRI was assessed for 
arterial enhancement pattern, late washout, arterioportal shunt, signal intensity on T2-
weighted image, intratumoral septa, enhancing tissue on subtraction images, and 
treatment response. Cox-regression analysis was performed to identify independent factors 
to predict TTP. TTP was calculated using the Kaplan-Meier method with the log-rank test. 
Per lesion, 30 achieved complete remission, 22 had a partial response, and the remaining 8 
lesions displayed stable disease on MRI. Arterial enhancement pattern, washout and 
enhancing tissue on subtraction images from MRI were associated with viable tumor on 
the last follow-up computerized tomography. Arterial enhancement, washout and 
enhancing tissue on subtraction images were significant predictors of TTP, but only 
enhancing tissue on subtraction images remained a significant predictor of TTP (P = 0.018) 
in the multivariate analysis. TTP was longer in the group without enhancing tissue on 
subtraction images compared to the group with enhancing tissue (601 days vs. 287 days, 
P < 0.001). Enhancing tissue on subtraction images from MRI after DEB-TACE is predictive 
for longer TTP.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary 
liver cancer and one of the common causes of cancer death (1). 
HCC can be cured through liver resection and liver transplanta-
tion, but many patients are not eligible for surgery when diag-
nosed. Transcatheter arterial chemoembolization (TACE) is a 
commonly used locoregional therapy for unresectable HCC in 
patients with preserved liver function. TACE is recommended 
for intermediate-stage HCC with multinodular disease and no 
vascular invasion or extrahepatic metastasis (2), but post-surgi-
cal survival benefits remain controversial (3-6). Nevertheless, 
evidence suggests that chemoembolization improves survival 
in patients with unresectable HCC (7, 8). TACE with drug-elut-
ing beads (DEB) was introduced, in which loaded drugs are de-
livered to target lesions by a transcatheter approach, and the 
beads elute drugs at controlled and sustained doses for a pro-
longed time. This approach allows higher and prolonged intra-
tumoral drug retention and low release of drug into systemic 
circulation (9-11). Previous study by Song et al. (12) reported 
that DEB-TACE showed better treatment response and delayed 
tumor progression compared with conventional lipiodol-based 
TACE (cTACE). DEB-TACE is associated with decreased liver 
toxicity and fewer drug-related adverse events such as post-em-
bolization syndrome or alopecia, allowing the use of higher dos-
es of chemotherapeutic agents. Consequentially, DEB-TACE 
offers higher rates of complete response, objective response, 
and disease control compared to cTACE (12-15).
 Multi-detector computed tomography (MDCT) and magnet-
ic resonance imaging (MRI) are usually used to evaluate treat-
ment response after cTACE or DEB-TACE. Imaging findings on 
computed tomography (CT) after DEB-TACE have been describ-
ed for HCC (16), but MRI findings after DEB-TACE and the rela-
tionship between MRI findings and time to progression have 
not been assessed fully. We evaluated MRI after DEB-TACE to 
see if there was a relationship between MRI findings and time 
to progression.
MATERIALS AND METHODS
Subjects
Between December 2009 and May 2012, 216 patients diagnosed 
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with HCC according to the American Association for the Study 
of Liver Diseases practice guidelines were treated with DEB-TA-
CE. Among them, patients were enrolled if they had liver MRI 
within 3 months after DEB-TACE. In total, 48 patients were in-
cluded in the study.
DEB-TACE treatment protocol
Doxorubicin and DEB (DC Bead®, Biocompatibles, Surrey, UK) 
amounts were chosen based on the extent of tumor burden. In 
this study, 2 or 4 mL of DEB with bead diameters ranging from 
100 to 300 μm or 300 to 500 μm were loaded with doxorubicin 
according to manufacturer’s guidelines. The endpoint for em-
bolization was stasis of blood flow in the arterial feeders to the 
tumor.
First follow-up MRI protocol
MRI examination was performed using two 3.0-T MR systems 
[(n = 42, Magnetom Tim Trio, Siemens Healthcare, Erlangen, 
Germany; n = 6, Achieva, Philips Medical Systems, Best, Neth-
erlands)]. The imaging protocol for the Magnetom Tim Trio sys-
tem included T1-weighted in-phase and out-of-phase images 
(TR, 150 ms; TE (in-phase/out-of-phase), 2.46 ms/ 1.23 ms; slice 
thickness, 6 mm; flip angle, 65°; ETL,1; matrix, 256 ×192; FOV, 
370 mm; band width, 1,628 Hz/Px), a breath-hold T2-weighted 
spin echo sequence (T2WI) (TR, 1,600 ms; TE, 81 ms; slice thick-
ness, 4 mm; flip angle, 140°; ETL, 11; matrix, 256×192; FOV, 370 
mm; band width, 260 Hz/Px), and diffusion-weighted images 
(DWI) with b values of 50, 400, and 800 sec/mm2 (TR, 5,400 ms; 
TE, 69 ms; slice thickness, 5 mm; flip angle, 90°; ETL, 1; matrix, 
192×108; FOV, 370 mm; band width, 1,736 Hz/Px). Precontrast 
images were acquired with three-dimensional T1-weighted fat-
suppressed gradient-echo images (T1WI) (TR, 2.54 ms; TE, 0.95 
ms; slice thickness, 2 mm; flip angle, 13°; ETL, 1; matrix, 256×192; 
FOV, 370 mm; band width, 814 Hz/Px).
 The imaging protocol for the Achieva MR system was similar: 
3 Echo T1-weighted fast field-echo (TR, 218.97 ms; TE, 2.30 ms; 
slice thickness, 5 mm; flip angle, 20°; ETL, 3; matrix, 160×199; 
FOV, 370 mm; band width, 2,701 Hz/Px), a breath-hold fat-sup-
pressed T2WI (TR, 1,000 ms; TE, 80 ms; slice thickness, 5 mm; 
flip angle, 90°; ETL, 75; matrix, 272 ×270; FOV, 370 mm; band 
width, 530 Hz/Px), DWI with b values of 50, 400, and 800 sec/
mm2 (TR, 1,612.8 ms; TE, 57.44 ms; slice thickness, 5 mm; flip 
angle, 90°; ETL, 29; matrix, 112×108; FOV, 360 mm; band width, 
2,157 Hz/Px), and precontrast images with three-dimensional 
T1-weighted fat-suppressed ultra-fast gradient-echo images 
(TR, 3.04 ms; TE, 1.44 ms; slice thickness, 4 mm; flip angle, 10°; 
ETL, 46; matrix, 256 ×258; FOV, 370 mm; band width, 723 Hz/
Px). The apparent diffusion coefficient (ADC) map from the DWI 
with three b values acquired from each magnet was made au-
tomatically using commercially available software with a mo-
no-exponential model.
 Contrast agent was injected intravenously through a 20-gauge 
intravenous catheter placed into a peripheral vein, followed by 
a 20-mL saline flush at a rate of 2 mL/sec. Gadodiamide (n = 30; 
Omniscan; GE Healthcare, Oslo, Norway; 0.1 mM/kg) was used 
as the contrast material. After contrast injection, dynamic im-
ages were obtained in four phases (arterial, portal, hepatic, and 
equilibrium) using the same sequence used for precontrast im-
ages with 18-20 sec for acquisition time and 30 sec time inter-
vals for each scan. The delay time for arterial phase imaging 
was determined using the MR fluoroscopic test bolus detection 
techni que. Subtraction images were acquired through post-im-
aging processing that subtracted the precontrast image from 
the arterial phase image.
Last follow-up CT protocol
The last follow-up CT was defined as the last CT examination 
obtained before death or the first CT examination to find pro-
gressive disease in this study. For follow-up CT examination, 
images were obtained with a 16-MDCT (Somatom Sensation 
16, Siemens Healthcare, Forchheim, Germany) and a 64-MDCT 
scanner (Somatom Sensation 64, Siemens Healthcare, Erlan-
gen, Germany and LightSpeed VCT, GE Health care, Milwau-
kee, Wis). An unenhanced scan was obtained before adminis-
tration of contrast media. All patients received a 2 mL/kg dose 
(total volume, < 150 mL) of nonionic contrast material (iopro-
mide; Ultravist 300, Bayer Schering Pharma, Wayne, NJ). A late 
arterial phase scan was obtained with a delay of 18 sec after at-
tenuation of the abdominal aorta reached 100 HU. Portal ve-
nous and delayed phase imaging were obtained with a delay of 
30 and 150 sec, respectively, after the end of the previous phase. 
Scanning parameters were as follows: 0.5-sec rotation time; 
100-120 kV; 200-250 mAs; 0.6-mm beam collimation; beam 
pitch, 1; and 3-mm slice thickness.
Image analysis on first follow-up MRI and treatment 
response
Follow-up images were reviewed in consensus by two radiolo-
gists with 6 and 5 yr of experience in abdominal imaging who 
did not perform the DEB-TACE and who were blinded to all clin-
ical information except that all patients had undergone DEB-
TACE. MRI images were reviewed in two sessions. Each image 
set (T2WI, precontrast T1WI, dynamic images involving arteri-
al, portal, hepatic, and equilibrium phases, subtraction image, 
HBP and DWI images) was evaluated and the following docu-
mented: (a) the pattern of arterial enhancement of treated tu-
mor [no enhancement, peripheral rim enhancement, periph-
eral nodular enhancement and solid enhancement (with en-
hancement in whole or mainly tumor)]; (b) the presence of wash-
out on late dynamic images involving portal, hepatic, and equi-
librium phases; (c) the presence of an arterioportal (AP) shunt; 
(d) tumor signal intensity on T2WI using a three-grade scale: 
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hyperintense, isointense, and hypointense compared with sig-
nal integrity of adjacent liver parenchyma; (e) the presence of 
intratumoral septa in the cystic or necrotic portion of the tumor 
(no septa, fine septa < 2 mm, or thick septa ≥ 2 mm); (f) ADC 
value of each tumor; (g) the presence of enhancing tissue on 
the subtraction image; and (h) treatment response according to 
the modified Response Evaluation Criteria in Solid Tumors 
(mRECIST). Treatment response of the target lesion according 
to mRECIST was evaluated as follows: complete response (CR), 
disappearance of any intratumoral arterial enhancement; par-
tial response (PR), at least a 30% decrease in the sum of diame-
ters of the viable (enhancement in the arterial phase) target le-
sion, taking as reference the baseline sum of the diameters of 
the target lesion; stable disease (SD), any cases not meeting the 
definition for partial response; and progressive disease (PD), an 
increase of at least 20% in the sum of the diameters of the viable 
(enhancing) target lesion, taking as reference the smallest sum 
of the diameters of the viable (enhancing) target lesion record-
ed since the start of treatment. Tumor treatment response was 
evaluated on the last follow-up CT according to mRECIST. Re-
currence of the treated tumor after DEB-TACE was defined as 
arterial enhancement that was newly developed in the non-en-
hancing portion of the treated tumor. Tumor recurrence was 
regarded as progressive disease.
Statistical analysis
The relationship between imaging findings on first follow-up 
MRI and detection of viable tumor on last follow-up CT was as-
sessed using Pearson’s chi-squared test or Fisher’s exact test. A 
P value less than 0.05 was considered to indicate a statistically 
significant difference. A cut-off ADC value was calculated to 
differentiate treated lesions with or without viable tumor by 
ROC curve and the diagnostic performance of the ADC value to 
predict the presence of viable tumor tissue using this threshold 
was assessed. For the calculation of TTP, disease progression as 
defined by mRECIST was used as an end point. The time to 
progression was defined as the time between DEB-TACE data 
and the date of the imaging study that identified disease pro-
gression among the follow-up imaging studies. Cox regression 
univariate analysis was used to identify independent factors to 
predict TTP among age, gender, American Joint Committee on 
Cancer (AJCC) staging classification, Barcelona Clinic Liver 
Cancer (BCLC) staging classification, and MRI findings. Hazard 
ratio and 95% confidence intervals were calculated for each 
factor. Each factor that was statistically significant on univariate 
analysis was tested in multivariate models. TTP for significant 
factor on multivariate model was calculated using the Kaplan-
Meier method and compared using the log-rank test. Statistical 
analyses were performed using SAS software version 9.2 (SAS. 
Cary, NC, USA).
Ethics statement
The study protocol was approved by the institutional review 
board of Severance Hospital (IRB No. 4-2014-0203). Informed 
consent was waived by the board.
RESULTS
Patient characteristics are summarized in Table 1. In total, the 
study included 36 men and 12 women with a mean age of 58 yr 
(age range, 35-77 yr) and 60 tumor nodules: 40 had one tumor 
lesion; 5 had two lesions; 2 had three lesions; and one had four 
lesions (36 nodules ≥ 3 cm and 24 nodules < 3 cm; mean size, 
3.2 cm; range 1.0-14.5 cm). DEBs were 100-300 μm in 24 lesions, 
300-500 μm in 31 lesions, and both 100-300 μm and 300-500 
μm in 5 lesions. All patients had liver cirrhosis. The Child-Pugh 
class for liver function was class A in 43 patients (89.6%) and 
class B in 5 patients (8.3%). The most common etiology of liver 
cirrhosis was viral hepatitis B (36 patients, 75%). The AJCC stag-
es were stage I in 13 (27.1%), stage II in 26 (54.2%), stage III in 6 
(12.5%), and stage IV in 3 (6.2%) patients. The BCLC stages were 
stage 0 in 11 (22.9%), stage A in 17 (35.4%), stage B in 13 (27.1%), 
and stage C in 7 patients (14.6%). The mean interval between 
DEB-TACE treatment and follow-up MRI examination was 33.2 
days (range, 21-61 days). The mean interval from the first DEB-
TACE to the last follow-up CT was 16.1 months (range, 1-33.3 
months). Twelve of the patients died during the follow-up peri-
od. The causes of death were multi-organ failure in 1 patient 
and disease progression in 11 patients. Based on the first fol-
Table 1. Baseline patient characteristics 
Characteristics No. of patients (n = 48)
Age (yr), mean (range) 58 (35-77)
Sex
   Men
   Women
36
12
Child-pugh class
   A
   B
   C
43
  5
  0
Risk factor of liver cirrhosis
   HBV
   HCV
   Alcoholics
36
  5
  7
AJCC stage
   I
   II
   III A
   III B
   IV A
13
26
  4
  2
  3
BCLC stage
   0
   A
   B
   C
11
17
13
  7
HBV, hepatitis B virus; HCV, hepatitis C virus; AJCC, American Joint Committee on 
Cancer; BCLC, Barcelona Clinic Liver Cancer.
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low-up MRI for each patient (n = 48), CR was achieved in 20 
(41.7%), PR in 21 (43.8%), and SD in 7 (14.6%) patients. Table 2 
shows a summary of the treatment responses per lesion accord-
ing to mRECIST as evaluated on the first follow-up MRI and last 
follow-up CT. Based on the first follow-up MRI, CR was achieved 
in 30 (50.0%) lesions. Residual tumors were detected in 30 le-
sions (50.0%), with PR in 22 (36.7%) and SD in 8 (13.3%) lesions. 
There was no case of progressive disease. In the assessment of 
treatment response for each lesion at last follow-up CT (n = 60), 
CR was achieved in 16 (26.7%), PR in 6 (10%), SD in 2 (3.3%) and 
PD in 36 lesions (60.0%) (Table 2).
Table 2. Treatment response per lesion on first MRI after DEB-TACE and last CT ac-
cording to mRECIST
Treatment response First follow-up MRI Last follow-up CT
Complete response 30 16
Partial response 22   6
Stable disease   8   2
Progressive disease   0 36
mRECIST, modified Response Evaluation Criteria in Solid Tumors; DEB, drug-eluting 
bead; TACE, transarterial chemoembolization; HCC hepatocellular carcinoma.
Table 3. Imaging findings on first MRI after DEB-TACE and viable tumor per-lesion 
evaluated on last CT
Images
No viable 
tumor
Viable  
tumor
P value
Arterial enhancement
   None/rim shape
   Peripheral nodular/solid
  4/11 
1/0 
    3/12
20/9 
< 0.001*
Washout
   Yes
   No
  0
16
24
20
< 0.001*
AP shunt
   Yes
   No
  9
  7
24
20
0.437
Signal intensity on T2
   Hyper
   Iso/Hypo
  2
13/1
  5
35/4
0.999
Intratumoral septa
   None
  < 2 mm/ ≥ 2 mm
14
2/0
34
3/7
0.486
Enhancing tissue on subtraction image
   Yes
   No
  0
16
34
10
< 0.001*
Total 16 44
*P value is statistically significant. DEB, drug-eluting bead; TACE, transarterial che-
moembolization; HCC hepatocellular carcinoma; AP, arterioportal; T2WI, T2-weighted 
image.
A
D
B
E
C
Fig. 1. A 61-yr-old man treated with DEB-TACE for HCC. (A) An arterial enhancing mass (white arrowhead) is noted on the MRI obtained before DEB-TACE. (B, C) The treated le-
sion shows peripheral rim enhancement on arterial phase (white arrow) (B), and equilibrium phase (C) of axial fat-suppressed T1-weighted 3D GRE images in the follow-up MRI 
acquired 36 days after DEB-TACE. (D) Rim enhancement (white arrow) is identified as being more prominent on the subtraction image between the precontrast image and the 
arterial phase image. (E) The treated lesion shows high-signal intensity on T2-weighted image. Tumor response was determined as complete response on the first follow-up MRI.
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Imaging findings on first follow-up MRI and viable tumor 
on last follow-up CT
Based on MRI image analysis of arterial enhancement patterns, 
seven target lesions were not enhanced on arterial phase and 
23 lesions showed rim enhancement on arterial phase (Fig. 1) 
(Table 3). Peripheral nodular enhancement was depicted in 21 
lesions (Fig. 2) and solid enhancement was observed in 9 le-
sions. The last follow-up CT detected viable tumor tissue in three 
of 7 lesions with no arterial enhancement (42.9%) and 12 of 23 
lesions with rim enhancement (52.2%). Viable tumor was iden-
tified in 20 of 21 lesions with peripheral nodular enhancement 
(95.2%), and in all 9 target lesions with solid enhancement 
(100%). In other words, 29 among thirty target lesions with pe-
ripheral nodular or solid enhancement pattern on arterial phase 
of first follow-up MRI also showed viable tumor tissue on the 
last follow-up CT. The presence of viable tumor was statistically 
different according to arterial enhancement pattern (no or rim 
shape enhancement vs. peripheral nodular or solid enhance-
ment) (P < 0.001). Washout on portal or equilibrium phases 
was found in 24 out of 60 target lesions, and viable tumor was 
detected on CT in all 24 lesions that showed washout on the 
late dynamic phase (100%) compared to 20 (55.6%) of the 36 le-
sions without washout (P < 0.001). All 34 lesions with enhanc-
ing tissue on subtraction images showed viable tumor tissue on 
the last follow-up CT (100%) (Fig. 3), compared to 10 (38.5%) of 
the 26 lesions with no enhancing tissue on subtraction images 
(P < 0.001). An AP shunt was found in 33 lesions. On T2WI, 7 
lesions had high-signal, 48 had iso-signal, and 5 had low-signal 
intensity. Intratumoral septa were detected in 12 lesions (20%), 
5 with thin and 7 with relatively thick septa. All 7 lesions with 
relatively thick septa and 3 of the 5 lesions with thin septa show-
ed residual viable tumor. There was no difference in the pres-
ence of viable tumor according to the presence of an AP shunt, 
signal intensity on T2WI, or intratumoral septa. The mean ADC 
value on the first follow-up MRI of target lesions with viable tu-
mor tissue on the last follow-up CT (n = 44) was 1.607 ×10-3 
mm2/sec, which was higher than that of lesions without viable 
tumor tissue (1.576 ×10-3 mm2/sec) (n = 16). The cut-off value 
A
D
B
E
C
F
Fig. 2. A 68-yr-old man treated with DEB-TACE for HCC. (A) A large HCC with heterogeneous enhancement in the right lobe of the liver is noted on the arterial phase image of 
the CT obtained before DEB-TACE. (B-C) After DEB-TACE, near total necrosis is achieved in the tumor, but a small nodular portion with enhancement (white arrow) on arterial 
phase (B) and late washout on equilibrium phase (C) of axial fat-suppressed T1-weighted 3D GRE images remains in the periphery of the tumor on the follow-up MRI taken 30 
days after TACE. (D) Arterial enhancement of the residual tumor (white arrow) is accentuated on the subtraction image. (E) The residual viable portion of tumor on T2-weighted 
image shows low signal intensity with peripheral dark rim (white arrow). (F) Treatment response of HCC after DEB-TACE was determined to be a partial response. Residual tu-
mor with arterial enhancement increased on a follow-up CT taken 66 days after DEB-TACE.
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calculated by ROC curve to differentiate treated lesions with or 
without tumor progression was 1.779 × 10-3 mm2/sec and the 
diagnostic performance of the ADC value to predict tumor pro-
gression using this threshold showed a sensitivity of 79.6%, spec-
ificity of 50%, and AUC of 0.583.
Time to progression
Univariate analysis using the Cox-regression test revealed that 
arterial enhancement (HR = 2.693, P = 0.004), presence of wash-
out (HR = 3.168, P = 0.001) and enhancing tissue on subtrac-
tion images (HR = 3.789, P = 0.001) were significant predictors 
of TTP (Table 4). Gender, age, tumor stages and other MRI find-
ings such as the presence of an AP shunt, the presence of intra-
tumoral septa, and signal intensity on T2WI were not significant 
Table 4. Univariate Cox-regression analysis of TTP after DEB-TACE according to im-
aging findings on the first MRI
Factors
Time to progression
HR 95% CI
Log-rank 
P value
Gender 0.770 0.347-1.708 0.520
Age 1.012 0.973-1.053 0.539
AJCC 0.967 0.436-2.141 0.933
BCLC 1.204 0.612-2.37 0.591
Tumor size 1.044 0.936-1.164 0.441
Arterial enhancement 2.693 1.352-5.362 0.004*
Washout 3.168 1.58-6.351 0.001*
AP shunt 0.983 0.505-1.913 0.959
Intratumoral septa 1.672 0.776-3.602 0.190
Signal intensity on T2WI 0.774 0.189-3.159 0.308
Enhancing tissue on subtraction image 3.789 1.789-8.023 0.001*
*P value is statistically significant. TTP, time to progression; DEB, doxorubicin-eluting 
bead; TACE, transarterial chemoembolization; CI, confidence interval; HR, hazard ra-
tio; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Can-
cer; AP, arterioportal; T2WI, T2-weighted image.
Table 5. Multivariate Cox-regression analysis of TTP after DEB-TACE according to 
imaging findings on the first MRI
Factors
Time to progression
HR 95% CI 
Log-rank
P value
Arterial enhancement 0.559 0.145-2.145 0.396
Washout 2.046 0.668-6.264 0.210
Enhancing tissue on subtraction image 3.953 1.271-12.291 0.018*
*P value is statistically significant. TTP, time to progression; DEB, drug-eluting bead; 
TACE, transarterial chemoembolization; CI, confidence interval; HR, hazard ratio.
Fig. 3. A 67-yr-old woman treated with DEB-TACE for HCC. (A) HCC is noted on the arterial phase image of the liver MRI acquired prior to treatment. (B) After DEB-TACE, an 
enhancing portion within the treated tumor is not detected on the arterial phase. (C) Meanwhile, subtle washout is suspected on the equilibrium phase of a follow-up MRI taken 
30 days after DEB-TACE. (D) A small arterial enhancing portion is noted on the subtraction image. (E) Detecting residual tumor on axial T2-weighted image is difficult.
A
D
B
E
C
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predictors of TTP. Based on the subsequent multivariate analy-
sis, however, only enhancing tissue on subtraction images (HR 
= 3.953, P = 0.018) was a significant predictor for shorter TTP 
(Table 5). TTP was statistically longer without enhancing tissue 
on the subtraction image (601 days without vs. 287 days with, 
P < 0.001).
DISCUSSION
MDCT and MRI are useful imaging modalities for evaluating 
treatment response and predicting prognosis after TACE (17-
22). In particular, evaluation of prognosis in diverse aspects have 
been investigated among diverse aspects beyond size criteria. 
Recently, radiologic CR achieved after first TACE on CT, EASL 
and mRECIST reponses, and ADC change relative to baseline 
on MRI have been reported as independent predictors for prog-
nosis after TACE (17, 20, 21). Our study showed that imaging 
findings detected on the first follow-up MRI obtained after DEB-
TACE for HCC can be used to predict TTP and the presence of 
viable tumor tissue on follow-up CT. Arterial enhancement, late 
washout, and enhancing tissue detected on subtraction images 
were significant imaging predictors for viable tumor on follow-
up MRI and only enhancing tissue detected on subtraction im-
ages was significant imaging predictor for TTP. Our findings are 
in agreement with other reports on imaging of target lesions af-
ter cTACE that residual enhancement and washout of target le-
sions are related to tumor recurrence, time to progression, and 
overall survival (5, 23). Chung et al. (16) found that progression 
of treated HCC was different according to arterial enhancement 
pattern on CT after DEB-TACE. This study also found that the 
presence of residual and recurrent tumor tissue on the last CT 
examination differed according to arterial enhancement pat-
terns on the first follow-up MRI. The likelihood that viable tu-
mor tissue will be detected during follow-up increases when 
the target lesion shows a peripheral nodular or solid enhance-
ment pattern on the arterial phase of the first follow-up MRI. 
These imaging findings show directly viable tumor. Therefore, if 
these findings are detected on first follow-up MRI, immediate 
additional treatment and close follow-up are strongly recom-
mended. Tumor recurrence was rare in treated lesions showing 
rim enhancement on arterial phase. The arterial enhancement 
pattern of rim enhancement may be associated with hyperemia 
or fibrosis rather than viable tumor or high possibility of tumor 
recurrence. It was impossible to classify signal intensities of DWI 
into a single group due to marked heterogeneity of DWI signal 
intensity for most lesions in this study although DWI has been 
reported a significant prognostic predictor after TACE. The di-
agnostic performance of the ADC value for predicting tumor 
progression using calculated threshold was also not excellent.
 In this study, MRI subtraction images were the most helpful 
for predicting the presence of viable tumor on follow-up CT and 
time to progression, more so than arterial phase images. The 
small arterial enhancing portion of an image, representing the 
residual viable tumor, can be accentuated on subtraction imag-
es, allowing the subtraction image to facilitate the detection of 
small viable tumors that are difficult to distinguish. Subtraction 
images can help identify residual viable tumor tissue in mark-
edly heterogenous masses or adjacent liver parenchyma dis-
playing various signal intensity changes after DEB-TACE involv-
ing necrosis, infarction, and hemorrhage, among others. When 
gadoxetic acid is used for MRI contrast, subtraction images may 
be helpful in detecting small residual tumors in some degraded 
images, due to the deleterious effect of gadoxetic acid on arteri-
al phase image quality (24).
 Follow-up study after TACE is usually performed by CT. Lipi-
odol accumulation within the tumor after cTACE with lipiodol 
can be seen as high attenuation on CT, which can make it diffi-
cult to evaluate lipiodol uptake on MRI due to variable signal 
intensities of the lipiodol (25). In contrast, particles used in DEB-
TACE do not affect attenuation or cause signal changes. Accor-
dingly, MRI offers better contrast for soft tissues and higher spa-
tial resolution with sensitivity than CT for the evaluation of tu-
mor response after DEB-TACE (25).
 Residual tumors that are nodular in shape with a smooth mar-
gin at the inner surface of the treated tumor and nearly complete 
necrotic change (as shown in Fig. 2) are difficult to detect after 
cTACE with lipiodol, but are often detected after DEB-TACE, 
possibly due to the different characteristics of the embolic ma-
terials in DEB-TACE. Gelfoam is prepared manually and arteri-
al obstruction is heterogeneous and lasts less than 72 hr (15). 
Accordingly, cTACE with lipiodol enables more chemoperfu-
sion than a real chemoembolization because the material can-
not occlude the arterial tumor vessels completely or perma-
nently (6). In addition, rapid separation of doxorubicin and lipi-
odol, due to differences in hydrophilic properties, and coales-
cence inside the infusion catheter or the blood vessel increases 
the droplet size in cTACE with lipiodol, compared to the con-
trolled and sustained drug elution with DEB-TACE (26). In this 
study, we sometimes observed that residual arterial enhancing 
portions within the treated tumor, corresponding to viable tu-
mor tissue, decreased during the initial few months of first and 
second imaging follow-up after DEB-TACE without additional 
treatment. We attributed these changes to sustained drug elu-
tion after DEB-TACE. The smaller bead diameters of DEB-TACE 
also achieve a more distal embolization than in cTACE with lip-
iodol, further obstructing collateral channels and necessitating 
superselective embolization (27). When small beads are used, 
extensive liquefactive and coagulative necrosis radiates out-
wards from the centers of the DC bead clusters (27). A stronger 
anticancer effect in the area exposed to the drug with DEB-TACE 
could increase the extent of necrotic changes within the tumor, 
resulting in a clearer margin between the necrotic and viable 
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portions.
 There were several limitations in this study. First, the study 
population was small. Second, we could not use histopatholog-
ic evaluation as the gold standard for the viable tumor portion. 
Instead, we considered local recurrence of target lesions on fol-
low-up imaging to indicate the presence of residual viable tu-
mor after DEB-TACE. There is the possibility of more false-neg-
ative cases due to an insufficient follow-up period. Third, the 
windows of follow-up imaging after treatment were relatively 
wide, each within 3 months. A fixed and more precise scan time 
after treatment would have made the study more homogenous 
and comparable.
 In conclusion, enhancing tissue on subtraction images from 
MRI after DEB-TACE was predictive for longer TTP.
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